Chin Kuo-Kai, Charu Vivek, O'Shaughnessy Michelle M, Troxell Megan L, Cheng Xingxing S
Stanford University School of Medicine, Stanford University, Stanford, California, USA.
Department of Medicine, Brigham and Women's Hospital, Brookline, Massachusetts, USA.
Kidney Int Rep. 2020 Feb 5;5(5):632-642. doi: 10.1016/j.ekir.2020.01.022. eCollection 2020 May.
Immune-complex deposition in the transplanted kidney can present as well-phenotyped recurrent or de novo glomerular disease. However, a subset, herein termed immune-complex glomerulopathy not otherwise specified (ICG-NOS), defies classification. We quantified, categorized, and characterized cases of transplant ICG-NOS occurring at a single US academic medical center.
We retrospectively reviewed our single-institution pathology database (July 2007-July 2018) to identify and categorize all cases of immune-complex deposition in kidney allografts (based on immunofluorescence microscopy). We extracted clinicopathologic and outcome data for ICG-NOS (i.e., immune complex deposition not conforming to any well-characterized glomerular disease entity).
Of 104 patients with significant immune deposits, 28 (27%) were classified as ICG-NOS. We created 5 mutually exclusive ICG-NOS categories: Full-house, Quasi-full-house, IgA-rich, C1q-rich, and C1q-poor. Overall, 16 (57%) patients met criteria for definite or possible allograft rejection, including 9 (32%) with antibody-mediated rejection (ABMR), 3 (11%) suspicious for ABMR, 1 (4%) with T-cell-mediated rejection (TCMR), and 9 (32%) with borderline TCMR. After a median follow-up of 2.3 (range, 0.1-14.0) years after biopsy, 7 (25%) allografts had failed and an additional 8 (29%) had persistent renal dysfunction (hematuria, 14%; proteinuria, 21%; and estimated glomerular filtration rate <60 ml/min per 1.73 m, 11%).
In contrast to prior studies, our findings suggest that ICG-NOS is not necessarily a benign glomerular process and that there may be an association between ICG-NOS and alloimmunity. Our immunofluorescence-based classification provides a framework for future studies aiming to further elucidate ICG-NOS pathogenesis and prognosis.
移植肾中的免疫复合物沉积可表现为特征明确的复发性或新发肾小球疾病。然而,有一部分病例(本文称为未另行特指的免疫复合物性肾小球病,即ICG-NOS)难以分类。我们对美国一家学术医疗中心发生的移植ICG-NOS病例进行了量化、分类和特征描述。
我们回顾性分析了单机构病理数据库(2007年7月至2018年7月),以识别和分类肾移植中所有免疫复合物沉积病例(基于免疫荧光显微镜检查)。我们提取了ICG-NOS的临床病理和转归数据(即免疫复合物沉积不符合任何特征明确的肾小球疾病实体)。
在104例有显著免疫沉积物的患者中,28例(27%)被分类为ICG-NOS。我们创建了5个相互排斥的ICG-NOS类别:满堂亮、准满堂亮、富含IgA、富含C1q和低C1q。总体而言,16例(57%)患者符合明确或可能的移植肾排斥标准,其中9例(32%)为抗体介导的排斥反应(ABMR),3例(11%)疑似ABMR,1例(4%)为T细胞介导的排斥反应(TCMR),9例(32%)为临界TCMR。活检后中位随访2.3年(范围0.1 - 14.0年),7例(25%)移植肾失功,另外8例(29%)有持续性肾功能不全(血尿,14%;蛋白尿,21%;估计肾小球滤过率<60 ml/min/1.73 m²,11%)。
与先前的研究不同,我们的研究结果表明ICG-NOS不一定是良性肾小球病变过程,且ICG-NOS与同种免疫之间可能存在关联。我们基于免疫荧光的分类为未来旨在进一步阐明ICG-NOS发病机制和预后的研究提供了一个框架。